Patients undergoing hematopoietic SCT (HSCT) display an airway neutrophilic inflammation before transplantation that persists over the years. In this study, we have investigated the cytokine profile over a period of 1 year in the sputum supernatant of patients who underwent HSCT. We have measured sputum supernatant levels of TNF-α, TGF-β1, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17 and IFN-γ in 49 HSCT patients and compared the results with those found in 40 chronic obstructive pulmonary disease (COPD) and 54 healthy subjects matched for age. Compared with healthy subjects, before transplantation, HSCT patients exhibited raised levels of IL-6 (P o0.001) and IL-8 (P o 0.05) while the other cytokines were generally poorly detectable. This picture was rather similar to that seen in COPD even if cytokine levels were much greater in the latter, with IL-8 being significantly greater in COPD than in HSCT patients (P o0.0001). In the 1 year following transplantation, sputum IL-6 and IL-8 did not differ from those in healthy subjects. Overall in HSCT patients, sputum IL-8 and IL-6 correlated with sputum neutrophil counts (r = 0.4, P o 0.0001; r = 0.42, P o 0.0001, respectively). In conclusion, sputum IL-6 and IL-8 may play a role in neutrophilic airway inflammation seen in patients undergoing HSCT.
INTRODUCTION
Allogeneic hematopoietic SCT (HSCT) is now widely used to treat many hematologic malignancies. Unfortunately, pulmonary complications are frequent after this type of transplantation and are a major cause of post-transplant mortality. 1 In a previous paper, we described the lung function status and the airway inflammatory profile of patients after HSCT using exhaled nitric oxide and induced sputum. 2 The principal observation was a progressive appearance of a restrictive lung function defect associated with a persistent airway neutrophilic inflammation after HSCT.
While high sputum neutrophil counts have been linked to an irreversible airway obstruction such as that in chronic obstructive pulmonary disease (COPD), 3 no airway obstruction was seen in patients who underwent HSCT. Our previous study based on the sputum and blood cell culture model highlighted the Th1 profile in the airway and blood compartment of COPD patients with raised levels of IFN-γ. 4 The purpose of this pilot study was to assess the sputum cytokine profile in patients who underwent HSCT. This may lead to a better understanding of the underlying molecular mechanisms linked to cellular inflammation. We measured soluble inflammatory mediators in the sputum supernatant from patients undergoing HSCT and compared the results with those obtained in COPD and healthy subjects.
In this study, we undertook a comprehensive sputum cytokine analysis looking at Th1, Th2 and Th17 cytokines in sputum supernatant. Additionally, we also measured pro-inflammatory (TNF-α, IL-6) and anti-inflammatory (IL-10) cytokines together with TGF-β1, a recognized factor involved in airway and lung remodeling. We also followed the evolution of sputum cytokine levels in the first year after HSCT and assessed their relationship with patient clinical parameters as well as their predictive value for the 1-year survival.
MATERIALS AND METHODS Subjects
Between January 2006 and October 2011, we followed 182 patients who underwent HSCT for hematological diseases at the University Hospital Center of Liege. Among them, we selected 49 patients who were reassessed 3, 6 and 12 months after HSCT for their pulmonary function test and exhaled nitric oxide measurement and in whom we obtained enough sputum materiel to measure cytokine level (see the flow chart in Figure 1 ). The characteristics of these patients are presented in Table 1 . The diagnoses were Hodgkin's lymphoma (n = 4), non-Hodgkin's lymphoma (n = 11), ALL (n = 1), CLL (n = 4), AML (n = 16), CML (n = 1), myelodysplastic syndrome (n = 6) and multiple myeloma (n = 6). The stem cells were obtained from a related donor in 15 patients and from an unrelated donor in 34. Eleven patients underwent a myeloablative conditioning regimen with either 8 Gy single dose or 12 Gy fractionated TBI and high-dose chemotherapy. GVHD prevention consisted in CYA or tacrolimus with (n = 6) or without (n = 5) short MTX (15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6 and 11). Thirty-eight patients underwent non-myeloablative conditioning consisting in low-dose TBI (2 Gy) with (n = 31) or without (n = 7) fludarabine (90 mg/m 2 ). Their immunosuppressive regimen associated tacrolimus and mycophenolate mofetil (45 mg/kg from day 0 to day 28 in the case of an HLA-identical sibling donor or day 42 in the case of an alternative donor). The diagnosis of acute GVHD was based on clinical findings according to commonly accepted diagnostic criteria. 5 It was confirmed by biopsy and was categorized as present (grade 2-4) or absent (grade 0-1), as previously described. 6, 7 Sixteen patients developed grade 2-4 acute GVHD and were treated with methylprednisolone. Diagnosis and grading of cGVHD were made using the National Institute of Health consensus criteria 8 (n = 21). Healthy controls (n = 54) were recruited by local advertisement in the hospital. None of them exhibited respiratory symptoms and all had normal spirometric results (FEV1480% predicted value) and none had airways hyperresponsiveness (provocative concentration of methacholine causing a fall in FEV1 of 20%416 mg/mL). They were well matched with patients undergoing HSCT according to age, gender and tobacco habits.
Forty COPD patients were recruited through the outpatient clinic and pulmonary rehabilitation center (University Hospital Center, Sart-Tilman, Liege). All the COPD patients fulfilled the criteria proposed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). 9 COPD patients were in stable condition at the time of sputum collection and no patients were studied within 8 weeks of having an upper tract infection or any exacerbations requiring change in maintenance treatment or oral steroid and antibiotic prescription. To avoid confounding factors influencing systemic inflammation, patients with significant comorbidities (such as diabetes mellitus or cancer) were excluded. Patients were matched to age and gender with patients undergoing HSCT.
This study was approved by the Ethics Committee of the Faculty of Medicine at Liege University and all subjects gave written informed consent for participation.
Sputum induction and processing
The sputum was induced on the same day after completion of lung function as previously described. 10 The whole sputum was collected in a plastic container, weighed and homogenized by adding three volumes of PBS, vortexed for 30 s and centrifuged at 2000 r.p.m. for 10 min at 4°C. Supernatant was separated from cell pellet and stored at − 80°C. The cells were resuspended in a solution containing 5 mM dithiothreitol without Ca ++ and Mg ++ and gently shaked for 20 min at room temperature. The cell suspension was then centrifuged again at 1600 r.p.m. at 4°C for 10 min and the cell count was performed using a manual haemocytometer. Cell viability was assessed by trypan blue exclusion and the differential leukocyte count performed on cytospins stained with May-Grünwald-Giemsa on 500 non-squamous cells. When squamous cells were 480%, the sample was considered inappropriate. Of the samples used for our study 90% had squamous cell count ranging from 0 to 50%.
Cytokines
The concentrations of TNF-α, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17 and IFN-γ were assessed by ELISA multiplex using Fluorokine Abbreviations: BMI = body mass index; COPD = chronic obstructive pulmonary disease; DLCO = the carbon monoxide diffusing capacity; FEV1 = forced expiratory volume in 1 sec; FVC = forced vital capacity; KCO = the carbon monoxide transfer coefficient; pred = predicted; RV = residual volume; TLC = total lung capacity. Results are expressed as mean ± s.d. except for exhaled nitric oxide (FeNO) expressed as median (IQR).
Sputum cytokine levels in HSCT C Moermans et al 110 and 143% for TNF-α, TGF-β1, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17 and IFN-γ, respectively.
Statistical analysis
Results are expressed as mean ± s.d. or median (interquartile range) according to the distribution of the data. Intergroup comparisons were made using the Kruskal-Wallis test followed by Mann-Whitney test in case of significance. Comparisons between values before and after HSCT were performed using Wilcoxon matched-pairs signed rank test for sputum cell counts and cytokine levels. Correlations between variables were assessed using the Spearman rank test. Differences were considered statistically significant when a two-sided P-value was o0.05.
RESULTS
Baseline comparison between HSCT, healthy and COPD As expected, COPD patients were characterized by greater total sputum cell counts and greater proportions of neutrophils and eosinophils compared with both healthy subjects and transplanted patients, whereas patients who underwent HSCT were intermediate between healthy subjects and COPD (Table 2) . Interestingly, both percentage and absolute epithelial cell counts were lower in patients undergoing HSCT compared with healthy subjects.
Results regarding cytokines are given in Table 3 . Baseline levels of IL-6 in the sputum supernatant of patients undergoing HSCT and COPD patients were greater compared with healthy subjects (P o 0.001 and P o 0.0001, respectively) ( Figure 2 ). Baseline levels of IL-8 were higher in COPD compared with healthy subjects and HSCT patients (P o0.0001 for both) and higher in patients with HSCT compared with healthy subjects (P o 0.05) (Figure 3 ). The levels of IL-4, IL-10, IL-13, IL-17, TNF-α and IFN-γ were undetectable in the large majority of patients and no difference was seen between the groups. TGF-β1 was more often detectable in HSCT patients 1 year after the transplantation than in healthy subjects (P o 0.01) and COPD (Po 0.01). IL-5 was more often detectable in COPD compared with healthy (P o0.01) ( Table 3) .
Longitudinal assessment of cytokines in HSCT Among the 49 HSCT patients recruited at baseline for cytokines measurement, only 17 produced adequate sputum samples at each visit until 1 year. There was no significant change in sputum cell counts over the 1-year follow-up with persistence of a high sputum neutrophil count (data not shown, in agreement with the results of our whole cohort 2 ). With respect to cytokines, we noted a significant decrease of IL-6 levels 3 months after HSCT compared to baseline (n = 38; from 50 pg/mL (21-96) to 30 pg/mL (10-66); P o 0.01)), but no difference was noted at 6 (n = 34; from 57 pg/mL (35-99) to 32 pg/mL (14-102)); P = 0.48) and 12 months (n = 17; from 45 pg/mL to 44 pg/mL (16-121); P = 0.74) (Figure 4 ). There was no significant change in IL-8 levels over time even if there was a trend for a reduced level at 3 months compared to baseline (P = 0.09).
Influence of chronic GVHD on sputum cells and cytokines There was no significant difference between patients who developed a chronic GVHD and those who did not with respect to sputum neutrophil count and sputum IL-6 and IL-8 levels (Table 1 , Supplementary Material).
Relationship between sputum cytokines and sputum cell counts and lung functions When pooling all time points, IL-8 was positively correlated with the sputum neutrophil (n = 175, r = 0.4, P o 0.0001) ( Figure 5 ) and eosinophil absolute numbers (n = 175, r = 0.32, P o 0.0001) and negatively with FEV1% predicted (n = 175, r = − 0.35, P o 0.0001) Table 2 . Sputum total and differential cell counts in patients and healthy subjects 
DISCUSSION
To the best of our knowledge, cytokines have not been measured in the sputum from patients undergoing HSCT so far. Our work shows, for the first time, that induced sputum can be used to describe the inflammatory profile in the context of HSCT. The patients displayed raised sputum levels of IL-6 and IL-8 compared with healthy subjects matched for age although the levels remained lower than those found in COPD. The other cytokines tested including pro-inflammatory or pro-fibrotic cytokines, as well as Th1 and Th2 remained undetectable in the majority of patients. Overall, we did not see dramatic changes in cells and sputum cytokines in the 1-year period that follows the transplantation although there is a signal for raised pro-fibrotic TGF-β1 1 year after HSCT. This pleiotropic cytokine was shown to have beneficial and detrimental effects in the context of HSCT especially because of its critical role as modulator of alloimmunity and its critical involvement in fibrosis.
11
IL-6 is a pleiotropic cytokine involved in many immunological pathways. It is not only released in acute inflammation but also plays a role in chronic inflammatory processes. 12 This cytokine is mainly produced by mononuclear phagocytic cells and the correlation we found between sputum IL-6 and sputum macrophages is in keeping with this cell source being important in patients undergoing HSCT. The irradiation and the chemotherapy prior to HSCT may be involved in the release of IL-6 into the airways of patients as was demonstrated in animal models. 13 In our study, the increase in IL-6 is slightly but not significantly lower than that seen in COPD, another neutrophilic airway disease, which was previously found to exhibit raised sputum IL-6.
14-16 IL-6 is thought to be pivotal in inducing IL-17-mediated neutrophilic inflammation. 17 In our series, IL-17 was poorly detectable in all our groups of patients despite satisfactory recovery in spiking experiments. Of interest, however, is the relationship we found between sputum IL-6 and sputum neutrophil counts, which may confirm the link between IL-6 and neutrophilic inflammation. Our paired analysis of samples collected over 1 year also suggest an early decrease in sputum IL-6 levels 3 months after HSCT though this is not confirmed at further time points. The reduction in the cytokine level might be linked to starting immunosuppressive treatment like CYA and tacrolimus, which can downregulate IL-6 expression. 18 Why this decrease is not confirmed at 6 months and 1 year is unclear but this might be related to a loss of statistical power as a result of a lower number of paired samples as the study went by. IL-8 is a key chemoattractant for neutrophils and its sputum level was repeatedly shown to be increased in a series of neutrophilic airway diseases such as COPD, cystic fibrosis and bronchiectasis. 16, 19, 20 Our study extends this series by showing raised sputum IL-8 in patients undergoing HSCT although the levels remained significantly lower than those found in COPD. The role of IL-8 in recruiting sputum neutrophils in HSCT patients was further supported by the clear correlation found between sputum neutrophil counts and IL-8 levels over the 1-year period of observation.
Bronchial epithelial cells are known to contribute to local release of IL-6 and IL-8 upon activation. In our series of HSCT patients, the bronchial epithelial cell count appeared to be lower than that seen in healthy subjects. We can speculate that irradiation and chemotherapy are likely to cause injury and structural alteration of the epithelial layer thereby promoting release of cytokines involved in inflammatory cell trafficking in the airways.
Of note is the fact that, although higher before transplantation, sputum levels of IL-6 and IL-8 in the 12 months following HSCT did not strikingly differ from those seen in healthy subjects, an observation that might relate to the strong immunosuppressive treatment received by the patients.
We wondered whether the baseline cytokine levels could have any prognostic value for the survival. The death rate at 1 year was 16% (8 out 49) and actually rather low in the series of patients studied here compared to the whole cohort in which mortality at 1 year was 29%. Consequently, it was unlikely to find any statistical difference in cytokine levels at baseline between those who died vs those who survived.
Other cytokines tested, including IL-4, IL-5, IL-10, IL-13, TNF-α, TGF-β1 and IFN-γ, were poorly detectable. As aforementioned for IL-17, the poor detection cannot be accounted for by the use of a mucolytic agent that would have disturbed the immunoassay as our samples were only homogenised by diluting them in PBS. Furthermore, our spiking experiments showed adequate recovery of all cytokines. One explanation for the poor detection may be linked to the fact that we used whole sputum instead of the plug thereby diluting somewhat the mediator concentration found in the supernatant. 21, 22 Although generally poorly detectable, TGF-β1 was more frequently detected at 1 year, but not at baseline, in HSCT patients (18%) compared with healthy (2%) and COPD (0%). This finding could be of pathophysiological interest for airway tissue remodelling that may appear after transplantation. Indeed, this major profibrogenic cytokine was widely implicated in airway fibrosis after lung irradiation. 23 Moreover, in the context of HSCT, TGF-β1 was observed to be increased in skin biopsies and serum of patients with cGVHD. 24 In our study, we did not observe differences of sputum TGF-β1 level between those who developed cGVHD and those who did not (data not shown). However, the low number of patients studied at 1 year post-HSCT was limited and these findings certainly need to be confirmed in a larger population. Similarly, IL-5 was more often detectable in COPD (15%) than in healthy subjects (0%), a finding in agreement with the observation that some COPD may display airway eosinophilia. 25, 26 There are other models looking at cytokines in the airway by using sputum samples. We previously showed that measuring cytokines after 24 h sputum cell culture could provide biological signals distinguishing asthmatics 27 and COPD 4 from healthy subjects. However, cellular sources that contribute to the supernatant content are more varied than those contributing to supernatant from the sputum cell culture model, mainly regarding the epithelial layer, which is not strongly represented in the sputum cell culture. This highlights the complexity of the system and the caution needed before drawing definitive pathophysiological conclusion from cytokine measurement in the airway.
We recognize that our finding needs caution in the interpretation as the number of sputum samples assayed at 1 year was rather low, which decreases the statistical power and may cause a bias of selection. The original part of our work is the investigation of the airway inflammatory status of patients undergoing HSCT by using the technique of induced sputum. Although the technique is relatively non-invasive, it has, however, not been simple to systematically obtain paired sputum samples of sufficient quality over the follow-up period for several reasons including death, poor health status of the patients and/or sometimes poor quality of collected material. This has certainly limited the statistical power of our cell and biochemical analyses and the assessment of their predictive values.
We can conclude that patients undergoing HSCT exhibit a neutrophilic airway inflammation associated with raised sputum levels of IL-6 and IL-8, a picture similar but developed to a lesser extent in comparison with COPD. Longer follow-up in larger groups of patients would be required to confirm these results and to better discern the potential interest of sputum cytokines as biomarkers of patient outcome after HSCT.
